Granules Launches Peptide and Particle Engineering Centres at IIT Hyderabad
In a significant boost to its research and development initiatives, Granules India Limited has inaugurated two advanced Centres of Excellence (CoE) at the Technology Research Park of the Indian Institute of Technology (IIT) Hyderabad. These centres are dedicated to peptide development and particle engineering, marking a strategic move to enhance the company’s capabilities in drug formulation and delivery systems.
Overview of the New Centres
The newly established CoE for peptide development and characterization is part of Granules’ Contract Development and Manufacturing Organization (CDMO) arm, Ascelis Peptides. This centre aims to focus on the development of cosmetic, therapeutic, and pharmaceutical peptides. The initiative is being undertaken in collaboration with Senn Chemicals AG, a Swiss CDMO subsidiary, which brings additional expertise and resources to the project.
Simultaneously, the CoE for particle engineering is set up to advance research on novel drug delivery systems. This includes the development of amorphous solid dispersions, which are crucial for improving the solubility and bioavailability of various pharmaceutical compounds.
Objectives of the Centres
The primary objectives of these Centres of Excellence include:
- Enhancing research capabilities in peptide and particle engineering.
- Developing innovative drug delivery systems.
- Advancing polymorph research and material science.
- Creating proprietary technologies for regulated markets.
- Facilitating first-to-file opportunities in the pharmaceutical sector.
Significance of the Initiative
Granules India Limited aims to replace earlier external and ad-hoc development approaches with a dedicated research platform. This shift is expected to:
- Enhance formulation performance.
- Support the creation of proprietary technologies.
- Accelerate breakthrough developments in drug formulation.
- Increase the company’s global competitiveness in the pharmaceutical industry.
Statements from Leadership
During the inauguration ceremony, Dr. Krishna Prasad Chigurupati, Chairman and Managing Director of Granules India, emphasized the importance of specialized infrastructure and scientific expertise in achieving the company’s CDMO ambitions. He stated, “With specialized infrastructure and deep scientific expertise, we are enhancing our CDMO ambitions, accelerating breakthrough development, and building differentiated technologies that elevate our global competitiveness.”
Collaboration with IIT Hyderabad
The collaboration with IIT Hyderabad is a pivotal aspect of this initiative. The institute is renowned for its cutting-edge research and innovation in various fields, including biotechnology and pharmaceuticals. By partnering with IIT Hyderabad, Granules India aims to leverage the academic institution’s expertise and resources to drive advancements in peptide and particle engineering.
Future Directions
As the pharmaceutical industry continues to evolve, the need for innovative drug delivery systems and effective therapeutic solutions becomes increasingly critical. The establishment of these Centres of Excellence positions Granules India at the forefront of research and development in the pharmaceutical sector. The company plans to focus on:
- Expanding its portfolio of therapeutic peptides.
- Developing advanced formulations that improve patient outcomes.
- Exploring new technologies for drug delivery systems.
Conclusion
Granules India Limited’s launch of the peptide and particle engineering centres at IIT Hyderabad represents a significant step forward in the company’s commitment to innovation and excellence in the pharmaceutical industry. By investing in research and development, Granules is not only enhancing its capabilities but also contributing to the advancement of drug delivery technologies that are vital for addressing the healthcare challenges of the future.
Note: This article is based on information available as of December 1, 2025, and aims to provide insights into the recent developments at Granules India Limited.
